Cimetidine, which is a histamine H2-receptor antagonist widely used in the management of peptic ulcer diseases, has been shown to interact with hepatic drug elimination via reduction of liver blood flo^1) as well as inhibition of drug metabolizing enzyme systems^2)-5). On the other hand, it has been suggested that ranitidine, which appears to be as effective as cimetidine^6), reduces hepatic blood flow^7), but has no effect on P-450 systems^8). However, no time-course study data have been compiled on the influence of cimeti dine and ranitidine on hepatic drug-metabolizing enzyme activity.
In the present study, the effects of cimetidine and ranitidine on hepatic monooxygenase activi ty were investigated by monitoring the change in daily urinary 6-hydroxycortisol (6-OHF) excretion, corrected by total 17-hydroxycortico steroids (17-OHCS) excretion, because 6-OHF is a polar metabolite of cortisol formed primarily by the mixed-function oxygenase system in the endoplasmic reticulum of hepatocytes( Fig. 1) subjects, the largest individual difference was 0.007, suggesting that this method is very useful in assessing the effect of a drug on the hepatic microsomal monooxygenase systems. These re sults are in good agreement with previous study11).
In contrast with the steadiness of the ratio of the ratio of 6-OHF to 17-OHCS during the ranitidine treatment (Fig.2) , the ratio was in fluenced by oral cimetidine administration at a 200mg dose four times a day, as illustrated in It has also been reported that ranitidine, which does not bind to cytochrome P-45022), has no effect on drug-metabolizing enzymes8). These findings are quite consistent with our data, although the indices used to assess drug-metabolizing activity differ 610 from ours.
Antipyrine is a valuable test drug most widely used to examine the influence on the activity of hepatic oxidative drug-metabolizing enzymes23), because it is rapidly and completely absorbed, is distributed in total body water with negligible binding to plasma protein, and is metabolized almost completely in the liver with a low extrac tion ratio10). However, the disadvantage of antipy rine as a model drug is that it is itself a mild enzyme-inducer in man, and can stimulate its own metabolism10). Therefore, repeated monitor ing of antipyrine clearance within a single study cannot be used. In addition, the use of antipyrine loading with repeated blood sampling might also be an objection to performing this test.
In view of these disadvantages, the monitoring of the disposition of an endogenous compound, 
